Evidence map›Paper›PMID 35878575›Full record

Trial reportNeuroImage. Clinical2022

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a.

Shannon Kolind, Shawna Abel, Carolyn Taylor, Roger Tam, Cornelia Laule, David K B Li, Hideki Garren, Laura Gaetano, Corrado Bernasconi, David Clayton and 2 more

Open access · goldAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in NeuroImage. Clinical, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. MWF of the corpus callosum is a robust measure of remyelination: Results from the ReBUILD trial.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. REUSED: A deep neural network method for rapid whole-brain high-resolution myelin water fraction mapping from extremely under-sampled MRI.Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society · 2023
    Article
  7. Review
  8. Article
  9. Exploring subcortical pathology and processing speed in neuromyelitis optica spectrum disorder with myelin water imaging.Journal of neuroimaging : official journal of the American Society of Neuroimaging
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Shannon KolindDepartment of Medicine (Neurology), University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada; Department of Radiology, University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada; Department of Physics and Astronomy, University of British Columbia, 6224 Agricultural Road, Vancouver V6T 1Z1, Canada; International Collaboration on Repair Discoveries (ICORD), University of British Columbia, 818 West 10th Avenue, Vancouver, BC V5Z 1M9, Canada. Electronic address: Shannon.Kolind@ubc.ca.
Shawna AbelDepartment of Medicine (Neurology), University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada.
Carolyn TaylorApplied Statistics and Data Science Group (ASDa), Department of Statistics, University of British Columbia, 3178-2207 Main Mall, Vancouver, V6T 1Z4, Canada.
Roger TamDepartment of Radiology, University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada; School of Biomedical Engineering, University of British Columbia, 251 - 2222 Heath Sciences Mall, Vancouver V6T 1Z3, Canada.
Cornelia LauleDepartment of Radiology, University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada; Department of Physics and Astronomy, University of British Columbia, 6224 Agricultural Road, Vancouver V6T 1Z1, Canada; International Collaboration on Repair Discoveries (ICORD), University of British Columbia, 818 West 10th Avenue, Vancouver, BC V5Z 1M9, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, 2211 West Mall, Vancouver V6T 2B5, Canada.
David K B LiDepartment of Radiology, University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada.
Hideki GarrenProthena Biosciences, 331 Oyster Point Boulevard, South San Francisco, CA 94080, USA.
Laura GaetanoF. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland.
Corrado BernasconiF. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, Basel 4070, Switzerland.
David ClaytonGenentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Irene VavasourDepartment of Radiology, University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada.
Anthony TraboulseeDepartment of Medicine (Neurology), University of British Columbia, 2775 Laurel Street, Vancouver V5Z 1M9, Canada.
University of British Columbia · CAInternational Collaboration On Repair Discoveries · CARoche (Switzerland) · CHProthena (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyelin water imaging is a magnetic resonance imaging (MRI) technique that quantifies myelin damage and repair in multiple sclerosis (MS) via the myelin water fraction (MWF).

objectiveIn this substudy of a phase 3 therapeutic trial, OPERA II, MWF was assessed in relapsing MS participants assigned to interferon beta-1a (IFNb-1a) or ocrelizumab (OCR) during a two-year double-blind period (DBP) followed by a two-year open label extension (OLE) with ocrelizumab treatment.

methodsMWF in normal appearing white matter (NAWM), including both whole brain NAWM and 5 white matter structures, and chronic lesions, was assessed in 29 OCR and 26 IFNb-1a treated participants at weeks 0, 24, 48 and 96 (DBP), and weeks 144 and 192 (OLE), and in white matter for 23 healthy control participants at weeks 0, 48 and 96.

resultsLinear mixed-effects models of data from baseline to week 96 showed a difference in the change in MWF over time favouring ocrelizumab in all NAWM regions. At week 192, lesion MWF was lower for participants originally randomised to IFNb-1a compared to those originally randomised to OCR. Controls showed no change in MWF over 96 weeks in any region.

conclusionOcrelizumab appears to protect against demyelination in MS NAWM and chronic lesions and may allow for a more permissive micro environment for remyelination to occur in focal and diffusely damaged tissue.

Indexed as

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingAntibodies, Monoclonal, HumanizedBrainDouble-Blind MethodHumansInterferon beta-1aMagnetic Resonance ImagingMyelin SheathRecurrenceWaterAntibodies, Monoclonal, HumanizedInterferon beta-1aocrelizumabWaterDemyelinationInterferon Beta-1aMultiple SclerosisMyelin Water ImagingOcrelizumabRemyelination

Identifiers

PMID35878575
PMCPMC9421448
OpenAlexW4285809715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.